Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group ACYW135 conjugate vaccine (Walvax Biotechnology Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent meningococcal conjugate vaccine (MCV4) developed by Walvax Biotechnology to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine utilizes capsular polysaccharides from each of the four serogroups, individually conjugated to a carrier protein (typically CRM197) to enhance immunogenicity and induce immunological memory, particularly in infants and young children. This conjugate technology converts the T-independent polysaccharide antigens into T-dependent antigens, allowing for a more robust and long-lasting immune response compared to plain polysaccharide vaccines. Walvax's MCV4 was approved by the China National Medical Products Administration (NMPA) in 2022 for use in children and adults, following clinical trials that demonstrated its safety and immunogenicity across a broad age range from 2 months to 55 years.
- Brand names
- Menno
- Other names
- Quadrivalent meningococcal conjugate vaccineMenACYW conjugate vaccineMeningococcal Group ACYW135 Conjugate Vaccine (CRM197)
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group ACYW135 conjugate vaccine (Walvax Biotechnology Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group ACYW135 conjugate vaccine (Walvax Biotechnology Co., Ltd.).